Inhibrx Biosciences, Inc. (INBX)
INBX Stock Price Chart
Explore Inhibrx Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze INBX price movements and trends.
INBX Company Profile
Discover essential business fundamentals and corporate details for Inhibrx Biosciences, Inc. (INBX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Jun 2024
Employees
156.00
Website
https://inhibrx.comCEO
Mark Paul Lappe
Description
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
INBX Financial Timeline
Browse a chronological timeline of Inhibrx Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$2.94.
Earnings released on 13 Aug 2025
EPS came in at -$1.85 surpassing the estimated -$2.92 by +36.64%, while revenue for the quarter reached $1.30M .
Earnings released on 14 May 2025
EPS came in at -$2.80 falling short of the estimated -$2.55 by -9.80%.
Earnings released on 17 Mar 2025
EPS came in at -$3.09 falling short of the estimated -$2.88 by -7.29%, while revenue for the quarter reached $100.00K .
Earnings released on 14 Nov 2024
EPS came in at -$2.84 surpassing the estimated -$3.06 by +7.19%.
Earnings released on 13 Aug 2024
EPS came in at $125.48 surpassing the estimated -$3.60 by +3.59K%, while revenue for the quarter reached $100.00K .
Earnings released on 3 Jun 2024
EPS came in at -$1.44 falling short of the estimated -$1.04 by -38.46%.
Dividend declared on 30 May 2024
A dividend of $0.85 per share was announced, adjusted to $0.85. The dividend was paid on 20 Jun 2024.
Earnings released on 28 Feb 2024
EPS came in at -$1.73 falling short of the estimated -$1.07 by -61.68%, while revenue for the quarter reached $1.63M , beating expectations by +3.17K%.
Earnings released on 9 Nov 2023
EPS came in at -$1.10 falling short of the estimated -$1.01 by -8.91%, while revenue for the quarter reached $119.00K , beating expectations by +138.00%.
Earnings released on 7 Aug 2023
EPS came in at -$1.08 falling short of the estimated -$1.02 by -5.88%, while revenue for the quarter reached $30.00K .
Earnings released on 8 May 2023
EPS came in at -$1.12 falling short of the estimated -$0.84 by -33.33%, while revenue for the quarter reached $17.00K , missing expectations by -88.67%.
Earnings released on 6 Mar 2023
EPS came in at -$0.95 falling short of the estimated -$0.80 by -18.75%, while revenue for the quarter reached $274.00K , missing expectations by -72.43%.
Earnings released on 7 Nov 2022
EPS came in at -$0.90 surpassing the estimated -$1.01 by +10.89%, while revenue for the quarter reached $278.00K , missing expectations by -56.11%.
Earnings released on 8 Aug 2022
EPS came in at -$0.97 falling short of the estimated -$0.84 by -15.48%, while revenue for the quarter reached $711.00K , missing expectations by -33.50%.
Earnings released on 9 May 2022
EPS came in at -$0.80 falling short of the estimated -$0.62 by -29.03%, while revenue for the quarter reached $915.00K , missing expectations by -17.01%.
Earnings released on 28 Feb 2022
EPS came in at -$0.55 falling short of the estimated -$0.53 by -3.77%, while revenue for the quarter reached $2.84M , beating expectations by +134.70%.
Earnings released on 9 Nov 2021
EPS came in at -$0.54 surpassing the estimated -$0.57 by +5.26%, while revenue for the quarter reached $2.51M , beating expectations by +67.20%.
Earnings released on 9 Aug 2021
EPS came in at -$0.55 falling short of the estimated -$0.51 by -7.84%, while revenue for the quarter reached $918.00K , beating expectations by +11.95%.
Earnings released on 13 May 2021
EPS came in at -$0.51 surpassing the estimated -$0.61 by +16.39%, while revenue for the quarter reached $863.00K , missing expectations by -14.52%.
Earnings released on 12 Mar 2021
EPS came in at -$0.47 surpassing the estimated -$0.50 by +6.00%, while revenue for the quarter reached $2.78M .
Earnings released on 13 Nov 2020
EPS came in at -$0.77 falling short of the estimated -$0.60 by -28.33%, while revenue for the quarter reached $5.83M .
INBX Stock Performance
Access detailed INBX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.